CSS
LVTX

Cubist Systematic Strategies’s LAVA Therapeutics LVTX Stock Holding History

Cubist Systematic Strategies’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-101
Closed – – 4460
2022
Q1 		$0 Sell
101
-300
-75% -$1.52K ﹤0.01% 3686
2021
Q4 		$2K Buy
401
+300
+297% +$1.97K ﹤0.01% 3421
2021
Q3 		$1K Buy
+101
New +$727 ﹤0.01% 2926

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cubist Systematic Strategies's LVTX Position: Q2 2022 in Review

Cubist Systematic Strategies sold out of LAVA Therapeutics (LVTX) in Q2 2022, closing a stake of 101 shares.

Cubist Systematic Strategies first reported a position in LVTX in Q3 2021 and held it in 3 quarters. The position peaked at $2K in Q4 2021. 17 funds tracked by Wall St. Rank hold LVTX as of Q2 2022.

  • Cubist Systematic Strategies reported no remaining LAVA Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 101 LAVA Therapeutics shares in Q2 2022.
  • Cubist Systematic Strategies first reported a position in LAVA Therapeutics in Q3 2021 and held it in 3 quarters.
  • Cubist Systematic Strategies's LAVA Therapeutics position peaked at $2K in Q4 2021.
  • 17 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2022.

Based on Cubist Systematic Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.